FMFabiola Medeiros

Fabiola Medeiros

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Fabiola Medeiros has a total of 7 co-authors. Here are the top co-authors by number of shared publications:

  • Horacio Maluf

    Department of Pathology and Laboratory Medicine, Cedars Sinai Medical Center, Los Angeles, California

    2 shared publications
  • Aviv Oren

    Department of Pathology and Laboratory Medicine, Cedars Sinai Medical Center, Los Angeles, CA

    1 shared publication
  • Bonnie Balzer

    Department of Pathology and Laboratory Medicine, Cedars Sinai Medical Center, Los Angeles, CA

    1 shared publication
  • Bonnie M.D. Balzer

    Department of Pathology and Laboratory Medicine, Cedars Sinai Medical Center, Los Angeles, California

    1 shared publication
  • Chau M. Bui

    Department of Pathology and Laboratory Medicine, Cedars Sinai Medical Center, Los Angeles, CA

    1 shared publication
  • Chau Minh Bui

    Department of Pathology and Laboratory Medicine, Cedars Sinai Medical Center, Los Angeles, California

    1 shared publication

Latest Publications

  • Stromal p16 and SATB2 Expression Does Not Distinguish Atypical Polypoid Adenomyoma (APA) From its Benign Mimics

    by Chau Minh Bui, Mahzad Azimpouran, Bonnie M.D. Balzer, Horacio Maluf, Fabiola Medeiros

    Atypical polypoid adenomyoma (APA) is a polypoid biphasic lesion of low malignant potential that arises in the lower uterine segment and uterine corpus. The diagnosis of APA is often challenging on biopsy and curettage specimens, and both benign and malignant processes need to be considered in the differential. Stromal expression of p16 and SATB2 have recently been shown to distinguish APA from myoinvasive endometrioid carcinoma. The authors hypothesized that p16 and SATB2 immunohistochemistry could also aid in the distinction of APA from benign adenomyomatous polyp and endometrioid adenomyoma. The study comprised 10 APAs, 7 adenomyomatous polyps, 11 endometrioid adenomyomas, and 10 myoinvasive endometrioid carcinomas. The majority of APAs showed moderate to strong, diffuse p16 and stromal expression. However, most adenomyomatous polyps and endometrioid adenomyomas also exhibited moderate to strong, focal to diffuse p16 stromal expression. SATB2 showed weak to moderate, focal to diffuse expression in the majority of APAs, adenomyomatous polyps and endometrioid adenomyomas. In contrast, p16 and SATB2 were negative to weak and focal in 90% of myoinvasive endometrioid carcinomas. Our findings demonstrate that p16 and SATB2 may be helpful in the differential diagnosis of myoinvasive endometrioid carcinoma and APA while not useful in separating APA from adenomyomatous polyp and endometrioid adenomyoma.


  • Human Epidermal Growth Factor Receptor 2 Overexpression/Amplification in Primary Ovarian Endometrioid Carcinoma

    by Chau M. Bui, Aviv Oren, Bonnie Balzer, Horacio Maluf, Fabiola Medeiros

    Human epidermal growth factor receptor 2 (HER2) expression has become increasingly helpful in predicting responses to anti-HER2 agents in gynecological cancers. This study retrospectively analyzed HER2 expression in 48 primary ovarian endometrioid carcinomas. HER2 immunohistochemistry was performed using the Ventana platform (Clone 4B5 monoclonal predilute) following the manufacturer’s protocol. HER2 expression was equivocal (score 2+) by image analysis in 2 cases (4.17%) based on the breast cancer criteria. Fluorescence in situ hybridization was negative for HER2 amplification in one case (International Federation of Gynecology and Obstetrics, grade 1) and positive in the other (International Federation of Gynecology and Obstetrics, grade 3). Our findings contribute to the growing evidence that HER2 is overexpressed in a small proportion of ovarian endometrioid carcinoma, and thus may serve as a potential therapeutic target in selected cases.